The jab targets patients with Lynch syndrome, who are at high risk of bowel and ovarian cancer

The jab targets patients with Lynch syndrome, who are at high risk of bowel and ovarian cancer

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The INTERCEPT-Lynch trial is part of a scientific collaboration…